High resolution mapping of the breast cancer tumor microenvironment using integrated single cell, spatial and in situ analysis of FFPE tissue
Authors: Janesick Amanda , Shelansky Robert , Gottscho Andrew D. , Wagner Florian , Rouault Morgane , Beliakoff Ghezal , de Oliveira Michelli Faria , Kohlway Andrew , Abousoud Jawad , Morrison Carolyn A. , Drennon Tingsheng Yu , Mohabbat Seayar H. , Williams Stephen R. ,   10x Development Teams, Taylor Sarah E.B. 
Published: October 2022

Single cell and spatial technologies that profile gene expression across a whole tissue are revolutionizing the resolution of molecular states in clinical tissue samples. Commercially available methods that characterize either single cell or spatial gene expression are currently limited by low sample throughput and/or gene plexy, lack of on-instrument analysis, and the destruction of histological features and epitopes during the workflow. Here, we analyzed large, serial formalin-fixed, paraffin-embedded (FFPE) human breast cancer sections using a novel FFPE-compatible single cell gene expression workflow (Chromium Fixed RNA Profiling; scFFPE-seq), spatial transcriptomics (Visium CytAssist), and automated microscopy-based in situ technology using a 313-plex gene panel (Xenium In Situ). Whole transcriptome profiling of the FFPE tissue using scFFPE-seq and Visium facilitated the identification of 17 different cell types. Xenium allowed us to spatially resolve these cell types and their gene expression profiles with single cell resolution. Due to the non-destructive nature of the Xenium workflow, we were able to perform H&E staining and immunofluorescence on the same section post-processing which allowed us to spatially register protein, histological, and RNA data together into a single image. Integration of data from Chromium scFFPE-seq, Visium, and Xenium across serial sections allowed us to do extensive benchmarking of sensitivity and specificity between the technologies. Furthermore, data integration inspired the interrogation of three molecularly distinct tumor subtypes (low-grade and high-grade ductal carcinoma in situ (DCIS), and invasive carcinoma). We used Xenium to characterize cellular composition and differentially expressed genes within these subtypes. This analysis allowed us to draw biological insights about DCIS progression to infiltrating carcinoma, as the myoepithelial layer degrades and tumor cells invade the surrounding stroma. Xenium also allowed us to further predict the hormone receptor status of tumor subtypes, including a small 0.1 mm2DCIS region that was triple positive forESR1(estrogen receptor),PGR(progesterone receptor), andERBB2(human epidermal growth factor receptor 2, a.k.a. HER2) RNA. In order to derive whole transcriptome information from these cells, we used Xenium data to interpolate the cell composition of Visium spots, and used Visium whole transcriptome information to discover new biomarkers of breast tumor subtypes. We demonstrate that scFFPE-seq, Visium, and Xenium independently provide information about molecular signatures relevant to understanding cancer heterogeneity. However, it is the integration of these technologies that leads to even deeper insights, ushering in discoveries that will progress oncology research and the development of diagnostics and therapeutics.